AMNEAL PHARMACEUTICALS, INC.
Last · NASDAQ$18.90-0.67 (-3.42%)close · yahoo · 10h ago
Market cap$6.58B348.3M sh
P/E · TTM38.6fwd 15.8 · eps 0.49
Beta1.22vs S&P 500
Div yield0.00%annual · TTM
52w range
$9.56$21.18
Volume3.5Msession
| Revenue | $3.1B |
|---|---|
| Operating income | $453.9M |
| Net income | $157.4M |
| Free cash flow | $-86.9M |
| Operating margin | 14.6% |
| Net margin | 5.0% |
| Return on equity | 476.5% |
| Period | TTM 2026-06-30 |
Loading chart…
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$0.23
Est. revenue
812.1M
Earnings transcripts
- Motley Fool
Amneal (AMRX) Q2 2026 Earnings Call Transcript
AMNEAL PHARMACEUTICALS, INC.
- Issuer webcast
Amneal Pharmaceuticals Third Quarter 2019 Earnings Conference Call
AMNEAL PHARMACEUTICALS, INC.
- Issuer webcast
Amneal Pharmaceuticals First Quarter 2019 Earnings Conference Call
AMNEAL PHARMACEUTICALS, INC.
- Issuer webcast
Amneal Pharmaceuticals Third Quarter 2018 Earnings Conference Call
AMNEAL PHARMACEUTICALS, INC.
- Issuer webcast
Amneal Pharmaceuticals Second Quarter 2018 Earnings Conference Call
AMNEAL PHARMACEUTICALS, INC.
- Issuer webcast
Amneal Pharmaceuticals Second Quarter 2022 Earnings Conference Call
AMNEAL PHARMACEUTICALS, INC.
Press & signals
- GlobeNewswire
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
- GlobeNewswire
Amneal Reports Second Quarter 2026 Financial Results
- Satelight
Amneal to Report Third Quarter 2026 Results on November 3, 2026
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans